nach oben

Reactions Weekly

Erschienen in:

01.06.2019 | Case report

Ceritinib/crizotinib

Treatment failure secondary to development of drug resistance: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Lee J, et al. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor. Clinical Lung Cancer 20: 215-221, No. 3, May 2019. Available from: URL: http://doi.org/10.1016/j.cllc.2018.12.020 - South Korea

Titel: Ceritinib/crizotinib
Treatment failure secondary to development of drug resistance: 3 case reports
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63643-4

Springer Medizin

Ceritinib/crizotinib

Treatment failure secondary to development of drug resistance: 3 case reports

Excerpt

Weitere Artikel der Ausgabe 1/2019

Multiple drugs

Echocardiograms after childhood cancer cost effective?

Digoxin

Afatinib

Ibrutinib

Irbesartan/ketamine

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Multiple drugs

Echocardiograms after childhood cancer cost effective?

Digoxin

Afatinib

Ibrutinib

Irbesartan/ketamine